论文部分内容阅读
中信国健药业是由中国中信集团有限公司旗下中国中信股份有限公司(原“中信泰富有限公司”)投资控股的生物医药高新技术企业。公司始终专注于抗体药物研发和产业化,作为一家以研发为导向的生物制药企业,公司成功构建了抗体药物的开发和产业化的平台,并掌握了核心技术,具备了持续开发新药的能力,公司的生产规模位居行业前列,产品在国内抗风湿生物制药领域市场占有率稳居首位。13年来,公司努力承担社会
CITIC Guojian Pharmaceutical is a biopharmaceutical high-tech enterprise invested and controlled by China CITIC Corporation (formerly known as “CITIC Pacific Ltd.”) under the CITIC Group Limited. The company has always focused on antibody drug development and industrialization. As a research and development-oriented biopharmaceutical company, the company has successfully constructed a platform for the development and industrialization of antibody drugs and mastered core technologies with the ability to continuously develop new drugs. The company’s scale of production among the forefront of the industry, products in the domestic anti-rheumatoid biopharmaceutical market share in the first place. For 13 years, the company has worked hard to shoulder the society